These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

67 related articles for article (PubMed ID: 8917400)

  • 21. Tumor targeting by covalent conjugation of a natural fatty acid to paclitaxel.
    Bradley MO; Webb NL; Anthony FH; Devanesan P; Witman PA; Hemamalini S; Chander MC; Baker SD; He L; Horwitz SB; Swindell CS
    Clin Cancer Res; 2001 Oct; 7(10):3229-38. PubMed ID: 11595719
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacological and toxicological aspects of 4-demethoxy-3'-deamino-3'-aziridinyl-4'-methylsulphonyl-daunorubicin (PNU-159548): a novel antineoplastic agent.
    Geroni C; Ripamonti M; Arrigoni C; Fiorentini F; Capolongo L; Moneta D; Marchini S; Della Torre P; Albanese C; Lamparelli MG; Ciomei M; Rossi R; Caruso M
    Cancer Res; 2001 Mar; 61(5):1983-90. PubMed ID: 11280756
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effective schedules of exposure of medulloblastoma and rhabdomyosarcoma xenografts to topotecan correlate with in vitro assays.
    Pawlik CA; Houghton PJ; Stewart CF; Cheshire PJ; Richmond LB; Danks MK
    Clin Cancer Res; 1998 Aug; 4(8):1995-2002. PubMed ID: 9717830
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Relation between 9-aminocamptothecin systemic exposure and tumor response in human solid tumor xenografts.
    Kirstein MN; Houghton PJ; Cheshire PJ; Richmond LB; Smith AK; Hanna SK; Stewart CF
    Clin Cancer Res; 2001 Feb; 7(2):358-66. PubMed ID: 11234891
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Quantitative analysis of cell-kill effects of anticancer drugs: consideration of both in vitro and in vivo experimental systems].
    Sugiyama Y; Kobayashi T; Inaba M
    Gan To Kagaku Ryoho; 1987 Dec; 14(12):3183-98. PubMed ID: 3318699
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Identification, characterization and potent antitumor activity of ECO-4601, a novel peripheral benzodiazepine receptor ligand.
    Gourdeau H; McAlpine JB; Ranger M; Simard B; Berger F; Beaudry F; Farnet CM; Falardeau P
    Cancer Chemother Pharmacol; 2008 May; 61(6):911-21. PubMed ID: 17622531
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A metronomic schedule of cyclophosphamide combined with PEGylated liposomal doxorubicin has a highly antitumor effect in an experimental pulmonary metastatic mouse model.
    Shiraga E; Barichello JM; Ishida T; Kiwada H
    Int J Pharm; 2008 Apr; 353(1-2):65-73. PubMed ID: 18155369
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Plasma, tumor, and tissue disposition of STEALTH liposomal CKD-602 (S-CKD602) and nonliposomal CKD-602 in mice bearing A375 human melanoma xenografts.
    Zamboni WC; Strychor S; Joseph E; Walsh DR; Zamboni BA; Parise RA; Tonda ME; Yu NY; Engbers C; Eiseman JL
    Clin Cancer Res; 2007 Dec; 13(23):7217-23. PubMed ID: 18056203
    [TBL] [Abstract][Full Text] [Related]  

  • 29. 2-Chloroethyl-3-sarcosinamide-1-nitrosourea, a novel chloroethylnitrosourea analogue with enhanced antitumor activity against human glioma xenografts.
    Marcantonio D; Panasci LC; Hollingshead MG; Alley MC; Camalier RF; Sausville EA; Dykes DJ; Carter CA; Malspeis L
    Cancer Res; 1997 Sep; 57(18):3895-8. PubMed ID: 9307267
    [TBL] [Abstract][Full Text] [Related]  

  • 30. SJG-136 (NSC 694501), a novel rationally designed DNA minor groove interstrand cross-linking agent with potent and broad spectrum antitumor activity: part 1: cellular pharmacology, in vitro and initial in vivo antitumor activity.
    Hartley JA; Spanswick VJ; Brooks N; Clingen PH; McHugh PJ; Hochhauser D; Pedley RB; Kelland LR; Alley MC; Schultz R; Hollingshead MG; Schweikart KM; Tomaszewski JE; Sausville EA; Gregson SJ; Howard PW; Thurston DE
    Cancer Res; 2004 Sep; 64(18):6693-9. PubMed ID: 15374986
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Chronopharmacology of antitumor effect induced by interferon-beta in tumor-bearing mice.
    Takane H; Ohdo S; Yamada T; Yukawa E; Higuchi S
    J Pharmacol Exp Ther; 2000 Aug; 294(2):746-52. PubMed ID: 10900256
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Antitumor activity of troxacitabine (Troxatyl) against anthracycline-resistant human xenografts.
    Gourdeau H; Genne P; Kadhim S; Bibeau L; Duchamp O; Ouellet F; deMuys JM; Bouffard DY; Attardo G
    Cancer Chemother Pharmacol; 2002 Dec; 50(6):490-6. PubMed ID: 12451476
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Evaluation of amrubicin with a 5 day administration schedule in a mouse model].
    Noguchi T; Ichii S; Morisada S; Yamaoka T; Yanagi Y
    Gan To Kagaku Ryoho; 1999 Aug; 26(9):1305-12. PubMed ID: 10478184
    [TBL] [Abstract][Full Text] [Related]  

  • 34. NTP technical report on the toxicity and metabolism studies of chloral hydrate (CAS No. 302-17-0). Administered by gavage to F344/N rats and B6C3F1 mice.
    Beland FA
    Toxic Rep Ser; 1999 Aug; (59):1-66, A1-E7. PubMed ID: 11803702
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Antitumor effects in mice of low-dose (metronomic) cyclophosphamide administered continuously through the drinking water.
    Man S; Bocci G; Francia G; Green SK; Jothy S; Hanahan D; Bohlen P; Hicklin DJ; Bergers G; Kerbel RS
    Cancer Res; 2002 May; 62(10):2731-5. PubMed ID: 12019144
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Schedule-dependent interaction between Doxorubicin and mTHPC-mediated photodynamic therapy in murine hepatoma in vitro and in vivo.
    Kirveliene V; Grazeliene G; Dabkeviciene D; Micke I; Kirvelis D; Juodka B; Didziapetriene J
    Cancer Chemother Pharmacol; 2006 Jan; 57(1):65-72. PubMed ID: 16001168
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antitumor activity of the novel vascular targeting agent ZD6126 in a panel of tumor models.
    Blakey DC; Westwood FR; Walker M; Hughes GD; Davis PD; Ashton SE; Ryan AJ
    Clin Cancer Res; 2002 Jun; 8(6):1974-83. PubMed ID: 12060643
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Monohydroxyethylrutoside, a dose-dependent cardioprotective agent, does not affect the antitumor activity of doxorubicin.
    van Acker SA; Boven E; Kuiper K; van den Berg DJ; Grimbergen JA; Kramer K; Bast A; van der Vijgh WJ
    Clin Cancer Res; 1997 Oct; 3(10):1747-54. PubMed ID: 9815559
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The schedule-dependent effects of etoposide in leukaemic cell lines: a function of concentration and duration.
    Liu WM; Joel SP
    Cancer Chemother Pharmacol; 2003 Apr; 51(4):291-6. PubMed ID: 12721756
    [TBL] [Abstract][Full Text] [Related]  

  • 40. NTP Toxicology and Carcinogenesis Studies of Pentachloroanisole (CAS No. 1825-21-4) in F344 Rats and B6C3F1 Mice (Feed Studies).
    National Toxicology Program
    Natl Toxicol Program Tech Rep Ser; 1993 Apr; 414():1-284. PubMed ID: 12616284
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.